Rising Teen Marijuana Abuse Outpaces Alcohol Decline: Study

Dec.05.2022
Rising Teen Marijuana Abuse Outpaces Alcohol Decline: Study
Marijuana abuse among US youths has increased by 245% since 2000, while alcohol abuse has steadily declined.

Since 2000, there has been a 245% increase in marijuana abuse among American teenagers, while alcohol abuse has steadily declined during the same period.


According to a nationally peer-reviewed study, intentional abuse and misuse reported to the National Poison Data System (NPDS) were tracked through the year 2020.


The investigation results published today in the peer-reviewed journal "Clinical Toxicology" have found that there were over 338,000 incidents of intentional abuse or misuse in American children aged 6 to 18 years old.


Most of the cases occurred in males (58.3%), with over 80% of all reported cases of exposure occurring in young individuals aged between 13 and 18. Overall, more than 32% of instances resulted in clinical outcomes worse than minor.


A new report has revealed changes in patterns over time. For instance, during the research period, Ritalin was the substance with the most reported use, but it peaked in 2006 and has since declined.


Furthermore, the year 2000 had the highest number of abuse cases involving contact with ethanol, but since then, incidents of children drinking alcohol have steadily declined over the years.


In contrast, cases of marijuana exposure remained relatively stable from the year 2000 to 2009 and then began to steadily increase from 2011 onwards, with an even greater increase in cases observed from the years 2017 to 2020.


Experts analyzing data attribute the increase in marijuana use to the growing popularity of edible marijuana products, which are now widely used throughout the country.


According to Dr. Adrienne Hughes, an assistant professor of emergency medicine at Oregon Health & Science University and one of the authors of the study, from 2000 to 2013, the number of cases of ethanol abuse exceeded the number of cases involving marijuana each year.


However, by 2014, this trend had reversed.


Since 2014, cases of exposure to marijuana have exceeded cases of exposure to alcohol every year, and the numbers have been increasing each year," said Hughes.


Though all rates of marijuana abuse are on the rise, the average monthly growth rate of marijuana consumption is the highest when compared with all other forms. This indicates that teenagers have shifted from smoking marijuana to other methods of consumption. Marijuana extracts, such as those used in marijuana electronic cigarette products, are also increasingly popular.


Hughes said, "These edible and electronic vaping products are typically marketed in a way that appeals to young people and are considered more independent and convenient.


Nevertheless, despite being perceived as having minimal harm, studies indicate that this is not necessarily the case.


According to Hughes, "While smoking marijuana typically leads to an immediate high, consuming it in an edible form can take several hours to take effect, which may cause some people to consume more and experience unexpected and unpredictable highs.


Since 2017, there has been a sharp increase in the number of children using marijuana, coinciding with a wave of decriminalization legislation in the United States. As of 2022, marijuana is legal for adult recreational use in 19 states and legal for medical use in 36 states.


Although marijuana is only legal for adults and not for children, the authors of this study argue that it makes it easier for children and adolescents to come into contact with the drug, and leads people to believe that it is safe.


Our research describes the rising trend of adolescent marijuana abuse, particularly those involving edible products," said Hughes.


These survey results highlight continued concern among people about the impact of rapid marijuana legalization on this vulnerable population.


In addition to marijuana, the study also revealed cases of teenage abuse of non-prescription drugs. Between 2001 and 2016, the highest number of drug abuse cases were related to dextromethorphan, a non-prescription cold and cough medication. Oral antihistamines were also among the most commonly abused drugs in this study.


Deaths caused by drug abuse are rare, occurring in only 0.1% of cases among 450 young people. The incidence of death is higher among males and teenagers aged 16-18. Opioids are most commonly associated with these deaths.


Furthermore, although there were 57,488 incidents involving children aged 6 to 12, these cases typically do not involve "traditional" drugs but rather vitamins, plants, melatonin, hand sanitizer, and other items.


The limitations of this study are restricted to exposure cases categorized as abuse or misuse. "It is possible that other cases of misuse or abuse may have been classified in another manner and therefore missed," the authors report.


2FIRSTS will continue to follow and report on this topic. Further updates will be posted on the '2FIRSTS APP'. Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

US ITC Judge Finds Glas Infringed Two JUUL Vape Patents, Recommends Restrictions on Related Imports——Glas Received FDA Marketing Authorization for Four Vape Pods in May 2026; Proposed Restrictions Remain Under Commission Review
US ITC Judge Finds Glas Infringed Two JUUL Vape Patents, Recommends Restrictions on Related Imports——Glas Received FDA Marketing Authorization for Four Vape Pods in May 2026; Proposed Restrictions Remain Under Commission Review
A U.S. International Trade Commission (USITC) administrative law judge issued an initial determination on October 20, 2026, finding that certain Glas vaping devices, cartridges and components infringed 12 claims across two patents asserted by JUUL, constituting a violation of Section 337 of the Tariff Act of 1930. The judge recommended a limited exclusion order and a cease and desist order against the Glas respondents. Five months earlier, the FDA authorized four Glas e-cigarette pods, including mango, blueberry and two menthol variants. The patent investigation concerns device and cartridge structures and is separate from FDA premarket review. The proposed import restrictions have not become final, and their product-level scope remains unresolved.
company
Nov.05
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine's Cabinet of Ministers adopted Resolution No. 1259 on October 15, 2026, increasing excise stamp production fees for tobacco products and e-cigarette liquids by approximately 30.5%, from UAH 0.1643 to UAH 0.2144 per stamp. Fees for alcoholic beverages rose by about 30.2%. Separately, Ukraine's parliament passed Bill No. 15532 on October 13, proposing to postpone the full implementation of electronic excise stamps and traceability for alcohol, tobacco and e-cigarette liquids from November 1, 2026, to July 1, 2027. Parliament cited additional testing, configuration and integration requirements. The bill was sent to the president for signature on October 19.
Regulations
Oct.21
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds American, a BAT subsidiary, showcased four Vuse Pro flavored e-cigarette pods and its VELO nicotine pouch portfolio at NACS Show 2026. Booth staff confirmed to 2Firsts that the Vuse Pro flavors are sold in the U.S., although they have not received FDA marketing authorization. BAT outlined plans to expand Vuse retail distribution and reported that VELO held a 30.5% year-to-date volume share of the U.S. modern oral nicotine category through August 2026. The booth also featured the newly launched VELO MAX range and merchandising displays combining cigarettes, vaping products and oral nicotine brands.
EXPO
Oct.09
PMI Expands Its Second Global and First Asian Business Services Hub in the Philippines, Serving 160 Markets and Scaling Up AI Capabilities
PMI Expands Its Second Global and First Asian Business Services Hub in the Philippines, Serving 160 Markets and Scaling Up AI Capabilities
Philip Morris International's PMI Business Solutions Philippines has expanded its global business services hub in Makati and plans to add more than 80 positions. Established in 2021 primarily to provide finance and IT support to about 20 markets, the center now employs 519 professionals delivering roughly 600 services across 160 markets. Its functions now span finance, human resources, IT, commercial operations, data analytics, supply chain and project management. PMI says the hub's next phase will focus on AI-enabled and higher-value work. The company did not disclose the size or investment cost of the expansion.
Sep.24
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives